New drug combo takes on advanced cancers in first human trial
Disease control
Recruiting now
This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…
Phase: PHASE1 • Sponsor: Hefei TG ImmunoPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC